pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update
The August 31, 2017 update has been issued by the pan-Canadian Pharmaceutical Alliance Office (pCPAO). The key highlights from the pCPAO since the last update are:
- Six new drug products have initiated pCPA negotiations, for a total of 47 active negotiations;
- Five negotiations have been completed, for a total of 168 joint negotiations; and
- One new drug product was added to the “No pCPA Negotiations” list, for a total of 54 products for which the pCPA has decided not to negotiate collectively or individually at the provincial-territorial level.
In addition to the information above, MORSE Consulting is tracking the number of products reviewed by CADTH that have yet to initiate negotiations with the pCPA – which we refer to as “under pCPA Consideration”. The latest update since July 31, 2017 is:
- Two new drug products have received recent CDEC or pERC recommendations, for a total of approximately 18 products under pCPA Consideration
Please see below for more details.
- Six new drug products have initiated pCPA negotiations since the last update, for a total of 47 active negotiations
Brand Name |
Generic Name |
Manufacturer |
Indication |
Recommendation Date |
Time to Negotiation* (Days)
|
|---|---|---|---|---|---|
Brilinta |
ticragrelor | AztraZeneca Canada | Prevention of atherothrombotic events with history of myocardial infarction | 2016-08-25 | 355 |
Descovy |
emtricitabine/ tenofovir alafenamide |
Gilead Sciences | HIV-1 infection | 2016-08-24 | 356 |
Hemangiol |
propranolol | Pierre Fabre Dermo-Cosmetique | Infantile hemangioma | 2017-02-21 | 175 |
Mictoryl |
propiverine | Duchesnay Inc. | Overactive Bladder | 2017-04-19 | 118 |
Odefsey |
emtricitabine/ rilpivirine/ tenofovir alafenamide |
Gilead Sciences | HIV-1 Infection | 2017-05-25 | 82 |
Stivarga |
regorafenib | Bayer Inc. | Metastatic and/or unresectable gastrointestinal stromal tumours (GIST) | N/A Initial recommendation: 2014-05-20 |
Presumed renegotiation |
*Approximation: Negotiation initiation date assumed to be mid-month for the purposes of the calculation
- Five negotiations have been completed/closed since the last update, for a total of 168 joint negotiations.
- Three negotiations were completed:
Brand Name |
Generic Name |
Manufacturer |
Indication |
Negotiation Initiation |
Duration* (Days) |
|---|---|---|---|---|---|
Avastin
|
bevacizumab | Hoffman La-Roche Limited | Genitourinary platinum resistant ovarian cancer | July, 2016 | 396 |
Avastin
|
bevacizumab | Hoffman La-Roche Limited | Metastatic colorectal cancer | January, 2016 | 578 |
Jakavi
|
ruxolitinib | Novartis Pharmaceuticals | Polycythemia vera | June, 2016 | 426 |
- Two negotiations were closed:
Brand Name |
Generic Name |
Manufacturer |
Indication |
Negotiation Initiation |
Duration * (Days)
|
|---|---|---|---|---|---|
Butrans |
buprenorphine | Purdue Pharma | Persistent pain of moderate intensity | May, 2017 | 92 |
Caprelsa |
vandetanib | Sanofi Genzyme | Medullary thyroid cancer | June, 2017 | 61 |
*Approximation: Negotiation initiation and end date assumed to be mid-month for the purposes of the calculation
- One new drug product was added to the “No pCPA Negotiations” list, for a total of 54 products for which the pCPA has decided not to negotiate collectively or individually at the provincial-territorial level
- Ninlaro (ixazomib; Takeda Pharmaceutical Company Limited) – Multiple Myeloma
Note: Received a “Does not Recommend” from pERC
Based on information collected by MORSE Consulting:
- Two new drug products received CDEC or pERC recommendations or notifications to implement since the last update, for a total of approximately 18 products under pCPA Consideration.
Please note; the date provided is the date of the Final Recommendation or Notification to Implement where applicable.
- Blincyto (blinatumomab; Amgen Canada; September 8, 2017) – pediatric acute lymphoblastic leukemia
- Keytruda (pembrolizumab; Merck Canada Inc; September 8, 2017) – non-small lung carcinoma (first line)
To receive updates similar to this one please be sure to sign up for MORSE Signals, our free e-mail newsletter service.
